Synopsis Clinical evidence suggests that the addition of pembrolizumab to chemotherapy resulted in significantly higher rates of response and longer progression-free survival than chemotherapy alone The present study aims to compare the efficacy and safety of pembrolizumab combined with pemetrexed/platinum chemotherapy or alone in patients with metastatic non-small cell lung cancer (NSCLC). This week’s “ MED FACT ” discusses a clinical study from The New England Journal of Medicine, “ Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer ”. April 2018. Authors : L. Gandhi; D.
Rodríguez ‑Abreu; S. Gadgeelet; et al. Key Takeaways: Adding pembrolizumab to standard chemotherapy significantly results in 50% lower the risk than with standard chemotherapy alone in NSCLC patients. Objective: To compare the combination of pemetrexed/platinum chemotherapy plus either…
